Effects of rolipram on the elevated plus-maze test in rats: a preliminary study

Abstract

The objective of the present study was to assess the behavioural effects of rolipram, a specific cAMP phosphodiesterase (PDE4) inhibitor, in the elevated plus-maze (EPM) test in rats. Results showed that rolipram at the highest dose tested (0.1mg/kg) increased the percentage of both time spent and entries into open arms, although a decrease of locomotor activity in the EPM test was also observed. In contrast, diazepam (3.0 mg/kg) exhibited the typical profile of an anxiolytic in the EPM test, increasing the percentage of time spent and entries into open arms as well as locomotor activity. A posterior statistical analysis, however, established that the effects of both rolipram and diazepam on parameters denoting anxiolytic-like activity were statistically independent from those reflecting locomotor activity reduction. Furthermore, the effects of both rolipram and diazepam were shown to be distinct from those exhibited by tryciclic antidepressant imipramine which did not show any anxiolytic-like effects in the EPM test, although a reduction of locomotor activity was also detected. Although these preliminary results suggest that rolipram may have some anxiolytic-like properties on the EPM test in rats, such an interpretation should be taken cautiously due to the observed effects on locomotor activity, which could complicate the interpretation of results from rolipram and other PDE4 inhibitors in the current test and in other anxiety animal models.

Keywords

anxiety behaviour diazepam elevated plus-maze imipramine rat rolipram

Get full access to this article

View all access options for this article.

References

Blanchard R J , Shepherd J K , Rodgers R J , Magee L , Blanchard D C (1993) Attenuation of antidepredator defensive behavior in rats following chronic treatment with imipramine . Psychopharmacology 110: 245–253

Bobon D , Breulet M , Gerard-Vandenhove M-A , Guiot-Go¤oul F , Plomteux G , Sastre-y-Hernandez M , Schratzer M , Troisfontaines B , von Frenckell R , Wachtel H (1988) Is phosphodiesterase inhibition a new mechanism of antidepressant action? Eur Arch Psychiat Neurol Sci 238: 2–6

Criswell H E , Knapp D J , Overstreet D H , Breese G R (1994) Effects of ethanol, chlordiazepoxide, and MK-801 on performance in the elevated-plus maze and on locomotor activity . Alcohol Clin Exp Res 18: 596–601

Critchley M A E , Handley S L (1987) Effects in the X-maze anxiety model of agents acting at 5-HT1 and 5-HT2 receptors . Psychopharmacology 93: 502–506

Cruz A P M , Frei F , Graeff F G (1994) Ethopharmacological analysis of rat behavior on the elevated plus-maze . Pharmacol Biochem Behav 49: 171–176

Dawson G R , Tricklebank M D (1995) Use of the elevated plus maze in the search for novel anxiolytic agents .TIPS 16: 33–36

Dunn RW , Corbett R , Fielding S (1989) Effects of 5-HT1A receptor agonists and NMDA antagonists in the social interaction test and the elevated plus maze . Eur J Pharmacol 169: 1–10

File S E , Johnston A L (1989) Lack of effects of 5HT3 receptor antagonists in the social interaction and elevated plus-maze tests of anxiety in the rat . Psychopharmacology 99: 248–251

Gao B , Cutler MG (1994) Effects of acute and chronic administration of antidepressants, imipramine, phenelzine and mianserine, on the social behavior of mice . Neuropharmacology 33: 813–824

10.

Griebel G , Misslin R , Vogel E , Bourguingnon J-J (1991) Behavioral effects of rolipram and structurally related compounds in mice: behavioral sedation of cAMP phosphodiesterase inhibitors . Pharmacol Biochem Behav 39: 321–323

11.

Griebel G , Blanchard D C , Agnes R S , Blanchard R J (1995) Differential modulation of antidepredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and £uoxetine . Psychopharmacology 120: 57–66

12.

Heaslip R J , Evans DY (1995) Emetic, central nervous system, and pulmonary activities of rolipram in the dog . Eur J Pharmacol 286: 281–290

13.

Horowski R , Sastre-y-Hernandez M (1985) Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports . Curr Ther Res 38: 23–29

14.

Imaizumi M , Miyazaki S , Onodera K (1994) Effects of a nonxanthine adenosine antagonist, CGS15943, and a phosphodiesterase inhibitor, Ro 20–1724, in a light/dark test in mice . Meth Find Exp Clin Pharmacol 16: 717–721

15.

Kehr W , Debus G , Neumeister R (1985) Effects of rolipram, a novel antidepressant on monoamine metabolism in rat brain . J Neural Transm 63: 1–12

16.

Moser P C (1989) An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone . Psychopharmacology 99: 48–53

17.

Nicholson C D , Challis R A J , Shahid M (1991) Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes . TIPS 12: 19–27

18.

O'Neill M F , Fernandez AG , Palacios J M (1996) GR 127935 blocks the locomotor and antidepressant-like effects of RU 24969 and the action of antidepressants in the mouse tail suspension test . Pharmacol Biochem Behav 53: 535–539

19.

Pellow S , Chopin P , File S E , Briley M (1985) Validation of open, closed arms entries in an elevated plus-maze as a measure of anxiety in the rat . J Neurosci Meth 14: 149–167

20.

Porsolt R D , Lengre A , McArthur R A (1991) Pharmacological models of depression. In Animal models in psychopharmacology: advances in pharmacological sciences. BirkhÌuser Verlag Basel, pp.137–159

21.

Schneider H H (1984) Brain cAMP response to phosphodiesterase inhibitors in rats killed by microwave irradiation or decapitation . Biochem Pharmacol 33: 1690–1693

22.

Schneider H H , Schmiechen R , Brezinski M , Seidler J (1986) Stereo-speci¢c binding of the antidepressant rolipram to brain protein structures . Eur J Pharmacol 127: 105–115

23.

Silvestre J S , Fernandez AG , Palacios J M (1999) Preliminary evidence for an involvement of the cholinergic system in the sedative effects of rolipram. Pharmacol Biochem Behav (in press).

24.

Wachtel H (1982) Characteristic behavioral alterations in rats induced by rolipram and other selective adenosine cyclic 3',5'-monophosphate phosphodiesterase inhibitors . Psychopharmacology 77: 309–316

25.

Wachtel H (1983) Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors . Neuropharmacology 22: 267–272

26.

Wachtel H (1990) The second-messenger dysbalance hypothesis of affective disorders . Pharmacopsychiatry 23: 27–32

27.

Wachtel H , Schneider H H (1986) Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoaminedepleted mice by an action beyond postsynaptic monoamine receptors . Neuropharmacology 25: 1119–1126

28.

Willard M , Misslin R , Vogel E , Desaubry L , Wermuth C , Bourguignon J-J (1990) Anxiolytic and sedative properties of BW A78U, a novel anticonvulsant adenine derivate . Pharmacol Biochem Behav 35: 85–88